Status:
ENROLLING_BY_INVITATION
Plasma Exosome RNA to Diagnose Prostate Cancer
Lead Sponsor:
Xijing Hospital
Collaborating Sponsors:
Shaanxi Provincial People's Hospital
Yan'an University Affiliated Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The aim of the present study is to investigate a RNA combination to diagnose prostate cancer.
Eligibility Criteria
Inclusion
- Blood prostate-specific antigen PSA\>4ng/dl;
- Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging, and PSMA PET/CT examination.
- The patient is willing to undergo prostate biopsy.
Exclusion
- Previous diagnosis of prostate cancer through prostate biopsy;
- History of other malignant tumors in the past two years;
- According to the research physician\'s judgment, serious complications may occur and affect the normal conduct of the experiment
Key Trial Info
Start Date :
March 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT06604130
Start Date
March 12 2021
End Date
December 31 2025
Last Update
November 28 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Lanzhou University
Lanzhou, Gansu, China, 730000
2
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China, 750000
3
Qinghai University Affiliated Hospital
Xining, Qinghai, China, 810000
4
Weinan Central Hospital
Weinan, Shaanxi, China, 714000